|
Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
|
10 February 2021 |
|
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
|
14 December 2020 |
|
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
|
06 November 2020 |
|
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
|
03 November 2020 |
|
New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
|
02 September 2020 |
|
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
|
17 July 2020 |
|
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
|
02 July 2020 |
|
Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
|
24 June 2020 |
|
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
|
22 June 2020 |
|
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
|
28 April 2020 |